As part of International Women's Day and this year’s theme, Balance the Scales, we celebrate women leaders strengthening Victorian innovation ecosystem and reshaping the future of healthcare globally.
Women leaders shaping the future of biomanufacturing
Strong leadership and diverse perspectives are helping drive the next phase of innovation in Victoria’s life sciences sector.
One such leader is Dr Bev Menner, Chief Executive Officer of Cell Therapies Pty Ltd. Under her leadership, the company is helping translate breakthroughs in cell and gene therapies into commercial scale manufacturing that can deliver life-changing treatments to patients.
Dr Menner brings deep scientific expertise together with a strong focus on collaboration and patient-centric care. Her leadership approach emphasis building diverse teams and creating environments where different perspectives contribute to better decisions and stronger partnerships.
For Dr Menner, balancing the scales means ensuring diversity exists across the entire organisation.
Diversity of knowledge, experience, leadership and problem-solving styles drives better science and stronger partnerships.
Women at the table help organisations challenge long-held assumptions, unlock innovation and broaden strategic thinking.
At Cell Therapies, diversity is embedded across the organisation. Women make up at least 60% of teams at every level, from the board and executive leadership, to people leaders and staff. Around one third of their team were born outside Australia, and the team collectively speak more than twenty languages.
Unlocking opportunities in cell & gene therapy manufacturing
Victoria is home to a world-class biomedical ecosystem that is advancing innovation in cell and gene therapies, an area rapidly reshaping MedTech globally.
With more than 2,000 clinical trials underway exploring treatments for cancers, neurological disorders and autoimmune diseases, advanced therapies are gaining momentum. These cutting-edge solutions often require localised manufacturing due to their unique nature as ‘living therapies.’
Dr Bev Menner believes Australia and the Asia-Pacific region have significant potential to lead in the delivery and scaling of these therapies.
Australia offers several advantages:
- Robust regulatory frameworks that support high-quality, safe and effective delivery
- A diverse and expert workforce capable of scaling complex manufacturing processes
- First-class medical research and facilities integrating scientific innovation with clinical application.
Through strategic collaborations and leveraging sovereign expertise, Cell Therapies Pty Ltd is playing an integral role in meeting the growing demand for next-generation therapies, both nationally and internationally.
Why diversity strengthens Victoria’s innovation ecosystem
Diversity is increasingly recognised as a driver of stronger innovation and better decision-making.
Across Victoria’s life sciences sector, diverse leadership teams bring broader perspectives to complex challenges—from scientific development to commercialisation and global partnerships.
Across Victoria’s life sciences sector, diverse leadership teams bring broader perspectives to solve complex challenges, from scientific development to commercialisation and global partnerships.
Leaders like Dr Menner’s demonstrate how inclusive leaders can accelerating industry growth while strengthening Victoria’s position as a global hub for MedTech and biomanufacturing.
Balancing the scales goes beyond representation; it entails building organisations where diverse expertise, perspectives and experiences help turn breakthrough science into real-world healthcare solutions.
Learn more about MedTech and Pharma opportunities.
About Cell Therapies Pty Ltd
Cell Therapies Pty Ltd is Australia’s leading contract development and manufacturing organisation focused exclusively on cell and gene therapies. It supports development from early clinical stages through to commercial-scale manufacturing, embedded within Melbourne’s biomedical precinct.
